ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.150,71
-0,10%
S&P 500
5.303,27
0,12%
US Dollar vs BRL
5,1047
0,00%
Bitcoin
66.788,51
-0,44%
Brent Oil
83,76
0,00%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Vaxxinity Inc (VAXX)

  7. Vaxxinity Inc (VAXX) Notícias

VAXX

Vaxxinity (VAXX)

Vaxxinity Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:VAXX
DataHoraFonteTítuloCódigoCompanhia
09/05/202417:24Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:VAXXVaxxinity Inc
09/05/202417:09Edgar (US Regulatory)Form DEF 14C - Other definitive information statementsNASDAQ:VAXXVaxxinity Inc
19/04/202419:53GlobeNewswire Inc.Vaxxinity Issues Shareholder LetterNASDAQ:VAXXVaxxinity Inc
19/04/202417:27GlobeNewswire Inc.Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common StockNASDAQ:VAXXVaxxinity Inc
28/03/202410:23GlobeNewswire Inc.Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual MeetingNASDAQ:VAXXVaxxinity Inc
27/03/202417:41GlobeNewswire Inc.Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate UpdatesNASDAQ:VAXXVaxxinity Inc
07/03/202412:32GlobeNewswire Inc.Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson’s Disease at AD/PD™ 2024NASDAQ:VAXXVaxxinity Inc
15/02/202418:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VAXXVaxxinity Inc
15/02/202410:00GlobeNewswire Inc.Vaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data PublishedNASDAQ:VAXXVaxxinity Inc
13/02/202410:00GlobeNewswire Inc.Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024NASDAQ:VAXXVaxxinity Inc
12/02/202419:02Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:VAXXVaxxinity Inc
30/01/202410:00GlobeNewswire Inc.Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of FloridaNASDAQ:VAXXVaxxinity Inc
18/01/202410:00GlobeNewswire Inc.Vaxxinity Announces Collaboration on Space Medicine Research with University of Central FloridaNASDAQ:VAXXVaxxinity Inc
03/01/202410:00GlobeNewswire Inc.Vaxxinity to Present at the 2024 J.P. Morgan Healthcare ConferenceNASDAQ:VAXXVaxxinity Inc
30/11/202319:03Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VAXXVaxxinity Inc
13/11/202320:50GlobeNewswire Inc.Vaxxinity to Present at Upcoming November Medical and Investor ConferencesNASDAQ:VAXXVaxxinity Inc
08/11/202310:30GlobeNewswire Inc.Vaxxinity Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:VAXXVaxxinity Inc
08/11/202309:53Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VAXXVaxxinity Inc
03/11/202317:31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VAXXVaxxinity Inc
29/08/202309:00GlobeNewswire Inc.Vaxxinity to Present at Upcoming Investor Conferences in SeptemberNASDAQ:VAXXVaxxinity Inc
21/08/202301:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:VAXXVaxxinity Inc
10/08/202309:00GlobeNewswire Inc.Vaxxinity Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical Efficacy Data from Phase 2a Trial in Alzheimer’s DiseaseNASDAQ:VAXXVaxxinity Inc
09/08/202309:00GlobeNewswire Inc.Vaxxinity Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:VAXXVaxxinity Inc
09/08/202308:31Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:VAXXVaxxinity Inc
27/07/202317:30GlobeNewswire Inc.Vaxxinity Appoints Peter Powchik, M.D., to Executive Vice President, Global Scientific DirectorNASDAQ:VAXXVaxxinity Inc
17/07/202309:00GlobeNewswire Inc.Vaxxinity Demonstrates Target Engagement of Toxic Alpha-Synuclein in Parkinson’s PatientsNASDAQ:VAXXVaxxinity Inc
26/06/202319:39Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:VAXXVaxxinity Inc
22/06/202317:31Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:VAXXVaxxinity Inc
22/06/202309:00GlobeNewswire Inc.Vaxxinity Announces UB-312 Successfully Met Primary Objectives of Phase 1 Clinical Trial in Parkinson’s DiseaseNASDAQ:VAXXVaxxinity Inc
09/05/202309:00GlobeNewswire Inc.Vaxxinity Reports First Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:VAXXVaxxinity Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:VAXX

Seu Histórico Recente

NASDAQ
LVRAW
Levere
EU
2932S
2932S
BIT
AUCO
L&G Gold Mining UCITS ET...
BIT
Q00399
Leonteq Securities
TSX
SLF
Sun Life Financial
TG
2S3
APA
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados